Details About Generic Salt ::  Amobarbi

Main Medicine Class:: Sedative and hypnotic,barbiturate   

(am-oh-BAR-bih-tahl SO-dee-uhm)
Amytal Sodium
Class: Sedative and hypnotic/barbiturate

 

Drugs Class ::

 Action Depresses sensory cortex; decreases motor activity; alters cerebellar function and produces drowsiness, sedation and hypnosis.

Indications for Drugs ::

 Indications Relief of anxiety; short-term therapy for insomnia; induction of preanesthetic sedation.

Drug Dose ::

 Route/Dosage

INSOMNIA

ADULTS: PO/IM/IV 65 to 200 mg at bedtime.

SEDATION

ADULTS: PO/IM/IV 30 to 50 mg bid or tid. CHILDREN: PO/IM 2 to 6 mg/kg/dose.

Contraindication ::

 Contraindications Hypersensitivity to barbiturates; history of addiction to sedative-hypnotic drugs; history of porphyria; severe liver impairment; respiratory disease with dyspnea; patients with nephritis.

Drug Precautions ::

 Precautions

Pregnancy: Category D. Lactation: Excreted in breast milk. Children: Safety and efficacy not established in children < 6 yr. Elderly: Reduce dosage. Drug dependence: Tolerance or psychologic and physical dependence may occur with continued use. Renal or hepatic impairment: Use with caution; reduce dosage.

PATIENT CARE CONSIDERATIONS


Drug Side Effects ::

 Adverse Reactions

CV: Bradycardia; hypotension; syncope. CNS: Drowsiness; agitation; confusion; headache; hyperkinesia; ataxia; CNS depression; paradoxical excitement; nightmares; psychiatric disturbances; hallucinations; insomnia; dizziness. GI: Nausea; vomiting; constipation. HEMA: Blood dyscrasias (agranulocytosis, thrombocytopenia). HEPA: Liver damage. RESP: Hypoventilation; apnea; laryngospasm; bronchospasm. OTHER: Hypersensitivity reactions (eg, angioedema, rashes, exfoliative dermatitis); fever; injection site reactions (eg, local pain, thrombophlebitis).

Drug Mode of Action ::  

 Action Depresses sensory cortex; decreases motor activity; alters cerebellar function and produces drowsiness, sedation and hypnosis.

Drug Interactions ::

 Interactions

Alcohol, CNS depressants: Depressant effects of these drugs may be enhanced. Anticoagulants, beta-blockers, calcium-channel blockers (eg, Verapamil) theophyllines: Activity of these drugs may be reduced. Anticonvulsants: Serum concentrations of carbamazepine, valproic acid and succinimides may be reduced. Valproic acid may increase barbiturate serum levels. Corticosteroids: Effectiveness may be reduced. Estrogens, estrogen-containing oral contraceptives: Effectiveness may be reduced.

Drug Assesment ::

 Assessment/Interventions

  • Obtain patient history, including drug history and any known allergies.
  • Ensure that serum bilirubin level has been determined before beginning long-term therapy, especially in patients with hepatic disease.
  • Monitor vital signs before and during IV infusion.
  • Assess sleep patterns and mental status before beginning therapy and monitor periodically during therapy.
  • Observe IV site during and after infusion. Extravasation or inadvertent intra-arterial injection may cause tissue necrosis, arterial spasm, thrombosis, or gangrene.
  • Monitor children and elderly patients for adverse reactions, including marked excitement, confusion, restlessness, or depression.
  • If hypersensitivity reaction develops, withhold dose and notify physician.
  • When administering by IV infusion, keep resuscitation equipment at bedside.
  • If signs of extravasation or phlebitis appear at injection site, discontinue IV infusion and notify physician.
  • Implement safety measures to prevent falls, especially with elderly patients.
  • Restrict amount of drug available to patient during early therapy.
OVERDOSAGE: SIGNS & SYMPTOMS
  Respiratory depression, CNS depression progressing to Cheyne-Stokes respiration, oliguria, tachycardia, hypotension, hypothermia, coma, shock, cessation of electrical activity in brain (extreme overdose)

Drug Storage/Management ::

 Administration/Storage

  • May be given in oral, IM (deep), or IV form. Do not administer SC.
  • Reconstitute solution with Sterile Water for Injection, rotating vial to mix. Do not shake vial. Solution should clear within 5 min.
  • Do not dilute with Lactated Ringer’s solution.
  • Do not administer if solution is discolored or if precipitate is present.
  • After reconstitution, inject solution within 30 min.
  • Do not exceed IV infusion rate of 1 ml/min or 100 mg/min. Over-rapid administration may result in respiratory depression, apnea, and hypertension.
  • To avoid tissue irritation, do no inject > 5 ml IM into any one site.
  • Store at room temperature. Do not freeze.

Drug Notes ::

 Patient/Family Education

  • Advise patient not to increase dosage or stop therapy without advice of physician.
  • Instruct patient to avoid alcohol, nicotine, and caffeine products.
  • Advise patient that drug may cause drowsiness, and to use caution while driving or performing other tasks requiring mental alertness.
  • Inform patient to report the following symptoms to physician: Excessive sleepiness, fatigue, nausea, vomiting.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

We would like to keep you updated with special notifications.